Johnson & Johnson (JNJ) - Fundamental Analysis Report 2026 (Updated)
Dear Investor, Welcome to Deep Research Global.
Executive TL;DR
Johnson & Johnson (JNJ) closed the first half of 2026 with worldwide sales of $49.4 billion, and management raised full-year guidance to a midpoint of $101.1 billion, officially clearing the $100 billion revenue threshold for the first time.
The Innovative Medicine engine is outrunning its Stelara loss-of-exclusivity headwind, with Darzalex crossing $4.21 billion and Tremfya surging 72.5% year over year to roughly $2.0 billion in Q2 2026 alone.
MedTech delivered a softer 4.5% reported growth in Q2 as Abiomed sales weighed on performance, while the planned DePuy Synthes Orthopaedics spinoff sets up a leaner, faster-growing device franchise.
Capital return is intact: the board approved a 3.1% dividend increase marking the 64th consecutive annual raise, and full-year adjusted EPS guidance was lifted to a $11.50 to $11.65 range.
Recommended - Read Full Reports
Read All Reports
Table of Contents
Executive TL;DR
Introduction
Johnson & Johnson Company Profile: Key Facts
Johnson & Johnson Investment Thesis
Johnson & Johnson Business Model Overview
Johnson & Johnson Revenue Analysis
Latest Quarterly Earnings and Guidance
Margins and Earnings Quality
EPS Trajectory
Cash Flow Mechanics
Balance Sheet Health
Johnson & Johnson Segment-by-Segment Teardown
Major Johnson & Johnson Competitors
Johnson & Johnson Strategic Context
Johnson & Johnson Valuation Framework
Bull, Base, and Bear Case Scenarios
Key Risks for Johnson & Johnson
Catalysts to Watch
Analyst Price Targets
My Final Thoughts
Official Sources and Data
Disclaimer: This analysis is for informational & educational purposes only and should not be construed as investment advice. Investors should conduct their own due diligence before making investment decisions. Past performance does not guarantee future results.
Introduction
Johnson & Johnson (JNJ) sits at an inflection point that few of its peers can claim.
The Stelara patent cliff, once billed as an existential threat, has been absorbed inside two quarters, and management has already flipped the narrative from “defending” 2026 to raising both revenue and adjusted EPS guidance twice in a row.
For investors watching the healthcare sector, the second half of 2026 matters because it will test whether the post-Kenvue, post-Stelara Johnson & Johnson can compound at mid-single-digit rates while funding a $14.6 billion neuroscience deal, a $13.1 billion cardiovascular deal, and a full Orthopaedics separation.
This report walks through the segments, the drugs, the devices, the competitive set, the valuation, and the risks with the granularity you need to make informed decision.
Let’s get started.
Johnson & Johnson Company Profile: Key Facts
Johnson & Johnson is the world’s most diversified healthcare company by revenue, now operating as a two-segment business focused on Innovative Medicine (branded prescription drugs) and MedTech (medical devices).
The company was founded in 1886, is headquartered in New Brunswick, New Jersey, and completed its separation of the Consumer Health business Kenvue in August 2023.
That structural shift is the single most important context for reading any comparison to pre-2023 financials.
Ticker: NYSE:JNJ
Exchange: New York Stock Exchange
Headquarters: New Brunswick, New Jersey, USA
Founded: 1886
CEO: Joaquin Duato
Segments: Innovative Medicine, MedTech
Employees: ~138,000 (as of latest 10-K)
Consecutive dividend increases: 64 years
Recent quarterly dividend: $1.34 per share
The company’s market capitalization sits near $606.67 billion, placing it among the two largest healthcare companies globally alongside Eli Lilly.
The post-Kenvue Johnson & Johnson is a materially different business than what long-tenured shareholders held five years ago.
Consumer products revenue no longer smooths the top line, so quarterly results now reflect the volatility of drug launches and device cycles more directly.
Management has spent the last three years redeploying separation proceeds into pharma and device tuck-ins rather than a mega-merger, a choice that has kept net debt manageable and preserved a AAA-adjacent credit profile.
Johnson & Johnson Investment Thesis
The Core Investment Case
The investment thesis rests on three legs.
First, the Innovative Medicine portfolio has cleared the Stelara loss-of-exclusivity air pocket faster than management guided at the start of 2026.
Second, MedTech’s cardiovascular pillar built through the Shockwave Medical acquisition is compounding at double-digit rates, offsetting slower orthopaedics growth ahead of the spinoff.
Third, the balance sheet still generates enough free cash flow to fund a 64-year dividend streak plus buybacks plus opportunistic M&A.
Why H2 2026 Is a Meaningful Window
H2 2026 is when several catalysts stack. Icotrokinra is progressing toward regulatory milestones for psoriasis, Tremfya continues to expand into inflammatory bowel disease indications, and nipocalimab is being positioned as a differentiated FcRn asset.
The Caplyta franchise, added through the Intra-Cellular Therapies acquisition that closed in April 2025, is scaling into major depressive disorder after its November 2025 FDA approval.
Key thesis drivers to watch in H2 2026:
- Continued Darzalex share gains in multiple myeloma
- Tremfya IBD ramp against Skyrizi and Rinvoq
- Caplyta MDD launch trajectory (post Nov 2025 approval)
- Shockwave IVL adoption in coronary and peripheral indications
- Ottava robotic surgery clinical trial readouts
- Progress toward DePuy Synthes Orthopaedics separationDefensibility of the Thesis
The Innovative Medicine segment has more than ten assets that either exceed $1 billion in annual sales or are on the path to do so, reducing concentration risk that plagues single-product biotech peers.
Multiple oncology growth drivers such as Darzalex, Carvykti, Tecvayli, Talvey, and Rybrevant are all in various stages of label expansion.
MedTech’s diversification across cardiovascular, surgery, orthopaedics, and vision provides a second, largely uncorrelated revenue stream. When drug pricing pressure hits pharma, procedure volumes usually normalize; when hospital capex is constrained, drug scripts still fill.
The company’s committed $55 billion U.S. investment covering manufacturing, R&D, and technology through 2029 aligns the company with domestic policy incentives at a moment when tariff and drug pricing risk are elevated for globally exposed peers.
Johnson & Johnson Business Model Overview
Two-Segment Architecture
Post-Kenvue, Johnson & Johnson runs a two-segment business.
Innovative Medicine covers branded, prescription pharmaceuticals across oncology, immunology, neuroscience, cardiovascular and metabolism, infectious disease, and pulmonary hypertension.
MedTech covers medical devices grouped into cardiovascular, surgery, orthopaedics, and vision.
The vision business includes both consumer contact lenses and surgical cataract equipment, which is why it sometimes gets grouped separately in analyst models.
Innovative Medicine therapeutic areas:
- Oncology (Darzalex, Erleada, Carvykti, Tecvayli, Talvey, Rybrevant, Balversa, Akeega)
- Immunology (Tremfya, Simponi, Remicade, Stelara legacy)
- Neuroscience (Spravato, Caplyta, Invega Sustenna/Trinza/Hafyera)
- Cardiovascular/Metabolism (Xarelto, Opsumit, Uptravi)
- Infectious Disease and Pulmonary HypertensionHow Revenue Is Generated
In Innovative Medicine the revenue model is patent-protected branded drug sales, priced through payer contracts in the US and largely tender-driven abroad. Gross margins on branded drugs typically run above 80% before rebates and access programs.
MedTech revenue is a mix of consumable sales tied to procedures (staplers, ablation catheters, intraocular lenses, IVL catheters) and capital equipment sales such as robotic platforms and cardiac support pumps. The consumable-to-capital ratio favors consumables, which supports recurring revenue quality.
The Innovative Medicine segment operates under adjusted income-before-tax margins near 42.5% in Q2 2026, a level that reflects the drug portfolio’s premium status.
Geographic Mix
Roughly half of the company’s revenue is generated in the United States. International markets include Europe, Japan, and China as the largest contributors, with emerging market exposure across Latin America, Southeast Asia, and the Middle East.
The US revenue skew is more pronounced in Innovative Medicine than in MedTech, which reflects US pharmaceutical pricing.
This creates a specific exposure to Medicare drug price negotiation policy and to the Inflation Reduction Act mechanisms.
Johnson & Johnson Revenue Analysis
Keep reading with a 7-day free trial
Subscribe to Deep Research Global to keep reading this post and get 7 days of free access to the full post archives.